Abstract
483 Norwegian breast cancer patients were screened for six different ataxia telangiectasia mutated (ATM) mutations previously found to account for 83% of the disease alleles in Norwegian ataxia telangiectasia (AT) patients. Only one carrier was found. These results provide no evidence in favour of an excess risk of breast cancer associated with heterozygosity for classical AT mutations, but remain consistent with a maximum 2.4-fold increased risk. © 2000Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA and Lønning PE (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811–814
Andersen TI, Heimdal KR, Skrede M, Tveit K, Berg K and Børresen AL (1994) Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Hum Genet 94: 665–670
Appleby JM, Barber JB, Levine E, Varley JM, Taylor AM, Stankovic T, Heighway J, Warren C and Scott D (1997) Absence of mutations in the ATM gene in breast cancer patients with severe responses to radiotherapy. Br J Cancer 76: 1546–1549
Athma P, Rappaport R and Swift M (1996) Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 92: 130–134
Bebb DG, Steele PP, Warrington PJ, Moffat JA and Glickman BW (1999) Absence of mutations in the ATM gene in forty-seven cases of sporadic breast cancer. Br J Cancer 80: 1979–1981
Bishop DT and Hopper J (1997) A-T-tributable risk?. Nat Genet 15: 22
Boder E (1985) Ataxia-telangiectasia: an overview. Kroc Foundation Series 19: 1–63
Broeks A, Urbanus JHM, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, Devilee P, Russell NS, van Leeuwen FE and van't Veer L (2000) ATM heterozygous germline mutations contribute to breast cancer susceptibility. Am J Hum Genet 66: 494–500
Bukholm IK, Nesland JM, Kåresen R, Jacobsen U and Børresen AL (1997) Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J Pathol 181: 140–145
Chen J, Birkholtz GG, Lindblom P, Rubio C and Lindblom A (1998) The role of ataxia-telangiectasia heterozygotes in familial breast cancer. Cancer Res 58: 1376–1379
Easton DF (1994) Cancer risks in A-T heterozygotes. Int J Radiat Biol 66: 177–182
FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP, Finkelstein DM, Isselbacher KJ and Haber DA (1997) Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 15: 307–310
Gatti RA, Tward A and Concannon P (1999) Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab 68: 419–423
Inskip HM, Kinlen LJ, Taylor AM, Woods CG and Arlett CF (1999) Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. Br J Cancer 79: 1304–1307
Izatt L, Greenman J, Hodgson S and Solomon E (1999) Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chrom Cancer 26: 286–294
Janin N, Andrieu N, Ossian K, Lauge A, Croquette MF, Griscelli C, Debre M, Bressac-de-Paillerets B, Aurias A and Stoppa-Lyonnet D (1999) Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br J Cancer 80: 1042–1045
Laake K, Ødegard A, Andersen TI, Bukholm IK, Kåresen R, Nesland JM, Ottestad L, Shiloh Y and Børresen-Dale AL (1997) Loss of heterozygosity at 11q231 in breast carcinomas: indication for involvement of a gene distal and close to ATM. Genes Chrom Cancer 18: 175–180
Laake K, Telatar M, Geitvik GA, Hansen RØ, Heiberg A, Andresen AM, Gatti R and Børresen-Dale AL (1998) Identical mutation in 55% of the ATM alleles in 11 Norwegian AT families: evidence for a founder effect. Eur J Hum Genet 6: 235–244
Laake K, Jansen L, Hahnemann JM, Brøndum-Nielsen K, Lönnqvist T, Kääriäinen H, Sankila R, Lähdesmäki A, Hammarström L, Yuen J, Tretli S, Heiberg A, Olsen JH, Tucker M, Kleinerman R and Børresen-Dale A-L (2000) Characterisation of ATM mutations in 41 Nordic families with ataxia telangiectasia. Hum Mutat 16: 232–246
Larson GP, Zhang G, Ding S, Foldenauer K, Udar N, Gatti RA, Neuberg D, Lunetta KL, Ruckdeschel JC, Longmate J, Flanagan S and Krontiris TG (1998) An allelic variant at the ATM locus is implicated in breast cancer susceptibility. Genet Test 1: 165–169
Nichols KE, Levitz S, Shannon KE, Wahrer DC, Bell DW, Chang G, Hedge S, Neuberg D, Shafman T, Tarbell NJ, Mauch P, Ishioka C, Haber DA and Diller L (1999) Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. J Clin Oncol 17: 1259
Olsen JH, Hahnemann JM, Børresen-Dale A-L, Brøndum-Nielsen K, Kleinermann R, Kääriäinen H, Hammarstrom L, Lähdesmäki A, Lönnqvist T, Sankila R, Seersholm N, Tretli S, Yuen J, Boice J and Tucker M (2000) Cancer in patients with ataxia-telangiectasia and their relatives – a collaborative study of the Nordic countries. JNCl in press
Oppitz U, Bernthaler U, Schindler D, Sobeck A, Hoehn H, Platzer M, Rosenthal A and Flentje M (1999) Sequence analysis of the ATM gene in 20 patients with RTOG grade 3 or 4 acute and/or late tissue radiation side effects. Int J Radiat Oncol Biol Phys 44: 981–988
Nichols KE, Levitz S, shannon KE, Wahrer DC, Bell DW, Chang G, Hegde S, Neuberg D, Shafman T, Tarbell NJ, Mauch P, Ishioka C, Haber DA and Diller L (1999) Heterozygous germline ATM mutation do not contribute to radiation-associated malignancies after Hodgkin's disease. J Clin Oncol 17: 1259
Regueiro JR, Porras O, Lavin M and Gatti RA (2000) Ataxia-telangiectasia – a primary immunodeficiency revisited. Immunol Allerg Clin North Am 20: 177–206
Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, Ashkenazi M, Pecker I, Frydman M, Harnik R, Patanjali SR, Simmons A, Clines GA, Sartiel A, Gatti RA, Chessa L, Sanal O, Lavin MF, Jaspers NGJ, Taylor AMR, Arlett CF, Miki T, Weissman TS, Lovett M, Collins FS and Shiloh Y (1995) A single ataxia telangiectasia gene with a product similar to Pl-3. kinase. Science 268: 1749–1753
Sedgwick RP and Boder E (1991) Ataxia-telangiectasia. In: Vinken PJ, Bruyn GW, Klawans HL (eds) Handbook of Clinical Neurology, pp 347–423. Elsvier Science: New York
Shayeghi M, Seal S, Regan J, Collins N, Barfoot R, Rahman N, Ashton A, Moohan M, Wooster R, Owen R, Bliss JM, Stratton MR and Yarnold J (1998) Heterozygosity for mutations in the ataxia telangiectasia gene is not a major cause of radiotherapy complications in breast cancer patients. Br J Cancer 78: 922–927
Swift M, Morrell D, Massey RB and Chase CL (1991) Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325: 1831–1836
Taylor AM, McConville CM, Rotman G, Shiloh Y and Byrd PJ (1994) A haplotype common to intermediate radiosensitivity variants of ataxia-telangiectasia in the UK. Int J Radiat Biol 66: 35–41
Vorechovsky I, Luo L, Lindblom A, Negrini M, Webster AD, Croce CM and Hammarström L (1996 a) ATM mutations in cancer families. Cancer Res 56: 4130–4134
Vorechovsky I, Rasio D, Luo L, Monaco C, Hammarstrom L, Webster AD, Zaloudik J, Barbanti-Brodani G, James M and Russo G (1996 b) The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveals no evidence for mutation. Cancer Res 56: 2726–2732
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Laake, K., Vu, P., Andersen, T. et al. Screening breast cancer patients for Norwegian ATM mutations. Br J Cancer 83, 1650–1653 (2000). https://doi.org/10.1054/bjoc.2000.1519
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1519
Keywords
This article is cited by
-
ATM and breast cancer susceptibility
Oncogene (2006)
-
Breast cancer genetics: What we know and what we need
Nature Medicine (2001)
-
Candidate tumour suppressor genes at 11q23–q24 in breast cancer: evidence of alterations in PIG8, a gene involved in p53-induced apoptosis
Oncogene (2001)